When Secondary Hypertension Subclinical Aldosteronism Might Be Hiding Behind “Normal” Blood Pressure Readings

If you’re in your mid-50s and have been told your high blood pressure is “resistant”—meaning it doesn’t budge much despite taking three or more medications—you may be wondering: What else could be going on? That’s where secondary hypertension subclinical aldosteronism comes into view. It’s not the usual suspect—no obvious muscle cramps, no dramatic potassium drops—but it’s surprisingly common in adults aged 55–64 and often overlooked. In fact, studies suggest up to 10–15% of people with resistant hypertension have this quiet endocrine driver, even when their potassium levels look perfectly normal on routine labs.

Many assume that if potassium is fine and symptoms are mild—or absent—then the cause must be “just aging” or “stress.” But that’s a misconception. Primary aldosteronism (PA) doesn’t always shout; sometimes, it whispers—through subtle changes in heart function, unexpected blood pressure responses, or lab patterns that only make sense when viewed together. The Endocrine Society’s 2023 Clinical Practice Guidelines reinforce this: screening shouldn’t wait for hypokalemia. Especially for adults over 50, early detection matters—not just for better BP control, but for protecting your heart long term.

Why Secondary Hypertension Subclinical Aldosteronism Matters—Even Without Low Potassium

Primary aldosteronism occurs when the adrenal glands make too much aldosterone, a hormone that tells your kidneys to hold onto salt and water—and, unfortunately, also promotes inflammation and fibrosis in blood vessels and the heart. In classic cases, this leads to low potassium (hypokalemia), high blood pressure, and sometimes fatigue or palpitations. But in subclinical forms—which account for roughly 70% of PA diagnoses—potassium stays within the “normal” range (3.5–5.0 mmol/L), masking the problem.

So why does this matter for adults 55–64? Because this age group faces a double vulnerability: arterial stiffness naturally increases with age, and undiagnosed aldosteronism accelerates damage to the heart’s relaxation phase (diastole) and small blood vessels. Think of it like a rubber band slowly losing its elasticity—except it’s happening inside your heart and arteries. Over time, that sets the stage for heart failure with preserved ejection fraction (HFpEF), stroke, or chronic kidney disease—even if your BP readings seem only moderately elevated.

The real red flag isn’t low potassium—it’s how your body responds. For example:

• A mildly elevated aldosterone-to-renin ratio (ARR) measured while upright (after 2 hours of standing or sitting upright) — values ≥30 ng/dL per ng/mL/hour raise concern, especially with concurrent BP >140/90 mm Hg.
• Early diastolic dysfunction on echocardiogram—like an E/e′ ratio >10 or reduced e′ velocity (<7 cm/sec)—can appear years before symptoms or overt heart failure.
• And perhaps most telling: a paradoxical rise in blood pressure after oral potassium supplementation. Yes—giving potassium should lower BP in most people with hypertension, but in subclinical PA, excess aldosterone blunts that effect and can even trigger sodium retention, causing BP to creep upward.

These clues aren’t random—they’re interconnected signs of mineralocorticoid excess quietly reshaping your cardiovascular system.

How to Spot It: Beyond the Standard Blood Test

Diagnosing secondary hypertension subclinical aldosteronism requires shifting from reactive to proactive testing—especially when standard treatments plateau.

First, timing matters. The aldosterone-to-renin ratio (ARR) is best drawn in the morning (8–10 a.m.), after at least 2 hours upright, and ideally while off interfering meds (like ACE inhibitors or ARBs—though your doctor will weigh risks vs. benefits before stopping them). An ARR ≥30 ng/dL per ng/mL/hour warrants confirmatory testing, such as a saline infusion test or oral sodium loading—both done under supervision.

Second, don’t overlook imaging and functional assessment. A dedicated echocardiogram—not just a quick “heart check”—should include tissue Doppler imaging to assess diastolic function. Look for terms like “impaired relaxation pattern,” “E/A reversal,” or “elevated left atrial volume index.” These aren’t just technical jargon; they reflect measurable, early-stage remodeling.

Third, consider context. Did your BP worsen after starting a potassium supplement—even a modest one like 20 mEq/day? That’s not typical—and it’s now recognized in the 2023 Endocrine Society guidelines as a potential functional clue. Similarly, unexplained microalbuminuria (tiny amounts of protein in urine) or progressive decline in estimated glomerular filtration rate (eGFR) may hint at aldosterone-driven kidney injury—even without overt hypertension spikes.

Importantly, screening isn’t just for those with sky-high numbers. Adults 55–64 with resistant hypertension (defined as BP >130/80 mm Hg on three meds—including a diuretic—or requiring four meds to reach goal) deserve evaluation—regardless of potassium, BMI, or family history.

Who Should Pay Special Attention?

You don’t need all the “classic” risk factors to be at risk. But certain profiles warrant closer attention:

• Adults aged 55–64 with resistant hypertension and any degree of left ventricular hypertrophy (LVH) on echo or ECG—even if mild.
• Those with a personal or family history of early-onset stroke (<60 years) or atrial fibrillation without clear structural cause.
• People whose blood pressure fluctuates unusually—like worsening in the afternoon or overnight non-dipping (less than 10% drop in BP during sleep).
• Anyone with incidentally discovered adrenal nodules (“incidentalomas”) on CT or MRI—even if <4 cm and deemed “benign.”

Also worth noting: women in this age group are diagnosed with subclinical PA at nearly twice the rate of men, possibly due to hormonal interactions and greater sensitivity to aldosterone’s cardiac effects. Yet they’re less likely to be screened—so speaking up about subtle symptoms (like persistent fatigue or unexplained swelling) can be pivotal.

Practical Steps You Can Take—Today

You don’t need to wait for your next appointment to begin supporting your cardiovascular health—especially if secondary hypertension subclinical aldosteronism is on your radar.

Start with sodium awareness—not just “no table salt,” but reading labels carefully. Processed foods, canned soups, bread, and deli meats often pack 500–1,000 mg of sodium per serving. Aim for ≤1,500 mg/day if you have resistant hypertension—this helps blunt aldosterone’s salt-retaining effect.

Prioritize potassium from food, not supplements—unless directed. Bananas, spinach, sweet potatoes, avocados, and white beans deliver potassium along with magnesium and fiber, which help balance sodium’s impact. Just remember: if your BP rises after potassium pills, pause and discuss it with your doctor before continuing.

Consider gentle movement daily—even 20 minutes of brisk walking—shown to improve endothelial function and reduce arterial stiffness. Also, aim for consistent, restorative sleep: poor sleep raises renin and sympathetic tone, potentially amplifying aldosterone’s effects.

For self-monitoring: use an upper-arm, cuff-style BP device validated for home use (look for certifications like AHA/ESH or ISO 81060-2:2018). Take readings at the same time each day—ideally mornings and evenings—for at least 5 days before appointments. Note posture (seated, rested 5 min), medication timing, and any symptoms like palpitations or shortness of breath.

Tracking your blood pressure trends can help you and your doctor make better decisions. Consider keeping a daily log or using a monitoring tool to stay informed.

See your doctor promptly if:

• Your home BP consistently exceeds 140/90 mm Hg despite current meds
• You develop new swelling in ankles or abdomen
• You notice irregular heartbeats or unexplained fatigue lasting more than two weeks
• Your echo report mentions “diastolic dysfunction,” “increased LV mass,” or “elevated LA volume”

A Gentle Closing Thought

Discovering that your high blood pressure might stem from something like secondary hypertension subclinical aldosteronism can feel overwhelming—but it’s actually hopeful news. Unlike many forms of hypertension, this one has targeted treatments: mineralocorticoid receptor antagonists (like spironolactone or eplerenone) often lower BP significantly and reverse early heart changes. In some cases, surgery (adrenalectomy) may be curative.

If you're unsure, talking to your doctor is always a good idea.

FAQ

#### What are the early signs of secondary hypertension subclinical aldosteronism?

Early signs often lack drama: subtle fatigue, mild swelling in the ankles, gradually worsening blood pressure control despite medications, or findings like early diastolic dysfunction on echo—even with normal potassium. A rising BP after potassium supplementation or an elevated upright aldosterone-to-renin ratio are key functional clues.

#### How common is secondary hypertension subclinical aldosteronism in adults over 60?

It’s more common than many realize—studies estimate 5–10% of adults aged 55–64 with resistant hypertension have subclinical PA. Prevalence rises slightly with age, though diagnosis rates remain low due to under-screening.

#### Can secondary hypertension subclinical aldosteronism occur with normal kidney function?

Yes—absolutely. Many patients have normal serum creatinine and eGFR early on. Aldosterone’s damage begins at the tissue level (blood vessels, heart, kidney tubules) before lab markers shift. Microalbuminuria or subtle changes in urinary sodium excretion may appear first.

#### Does stress cause secondary hypertension subclinical aldosteronism?

No—stress doesn’t cause it, but it can worsen it. Chronic stress activates the sympathetic nervous system and RAAS, potentially amplifying aldosterone’s effects and making BP harder to control. Managing stress supports treatment but doesn’t replace the need for proper diagnosis.

#### Is an adrenal CT scan enough to rule out secondary hypertension subclinical aldosteronism?

Not quite. A normal CT scan rules out large adrenal tumors—but subclinical PA often stems from bilateral adrenal hyperplasia (BAH), which appears normal on imaging. Functional testing (like ARR + confirmatory tests) is essential. Imaging alone misses up to 60% of cases.